Company intelligence / Profile preview

Nobias Therapeutics

Mountain View, California, United Statesnobiastx.com ↗

Ownership: Private
Employees: ~1
Development stage: Phase 2

Overview

Reported positive data from a Phase 2 clinical trial of lead program NB-001 for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome in children

Therapeutic areas: Rare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NB-001

Phase 2

Indications: 22q11 deletion syndrome

Partnerships

Relationships with pediatric academic medical centers across North America

Beyond the preview

Go deeper on Nobias Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nobias Therapeutics.

Explore the full profile